Stay informed with the latest updates for the inheritable blood disorders community.

Industry
Researchers Report Advances in Plant-based Hemophilia A Therapy
Researchers Report Advances in Plant-based Hemophilia A Therapy
Industry
Achillion’s New HCV Treatment Performing Well in Phase 2 Trial
Achillion’s New HCV Treatment Performing Well in Phase 2 Trial
Industry
Expression and ABL to Develop and Market High-Yield, Low-Cost rFVIII
Expression and ABL to Develop and Market High-Yield, Low-Cost rFVIII
Industry
BAX 855 Performs Well Prophylactically in Phase 3 Trial
BAX 855 Performs Well Prophylactically in Phase 3 Trial
Industry
BeneFIX® Performs Well in Prophylaxis Trial
BeneFIX® Performs Well in Prophylaxis Trial
Industry
FDA Approves Baxter’s RIXUBIS for Children with Hemophilia B
FDA Approves Octagam® 10% for Chronic ITP
Industry
FDA Approves Baxter’s RIXUBIS for Children with Hemophilia B
FDA Approves NovoSeven® RT for Glanzmann’s Thrombasthenia
Industry
Sangamo and Pfizer Announce Interim Gene Therapy Findings
Bayer and Dimension Partner to Develop Novel Hemophilia A Gene Therapy
Industry
FDA Approves Baxter’s RIXUBIS for Children with Hemophilia B
FDA Approves Biogen’s ELOCTATE™ for Hemophilia A
Industry
CSL Study Data Show Longer Intervals Between FIX Infusions
CSL Study Data Show Longer Intervals Between FIX Infusions
Industry
Novo Nordisk Presents NovoEight® Data at WFH Congress
Novo Nordisk Presents NovoEight® Data at WFH Congress
Industry
Federal 340B Drug Pricing Program in the News
Biogen and Sobi Announce Factor Donations at WFH Congress
Industry
Bayer Announces 2014 BHAP Winners
Bayer Announces 2014 BHAP Winners
Industry
Baxter Highlights Pipeline Products at WFH Congress
Baxter Highlights Pipeline Products at WFH Congress
Industry
BeneFIX® Performs Well in Prophylaxis Trial
Bayer’s Kogenate®FS Approved for Adult Prophylaxis